Adrian Kilcoyne

Abstract 3724: Exogenous IL-2 administration promotes circulating T-cell levels, persistence and therapeutic efficacy of allogeneic UCART20x22 in a B-cell lymphoma mouse model

Shipra Das, Hana Cho, Marco Rotondi, Isabelle Chion-Sotinel et autres

us, fr (code pays fourni par la source)

Weight based dosing of alemtuzumab as part of an enhanced lymphodepletion regimen may mitigate the risks of over and underexposure and improve response rates : Analysis of the nathali-01 trial

Xenia Naj, Laurent Poirot, Vivian Dai, P Vermeulen et autres

us (code pays fourni par la source)

In vitro evidence supporting the use of exogenous IL-2 support for allogeneic UCART22 cells to treat heavily pretreated R/R B-ALL patients

Laurent Poirot, P Vermeulen, Xenia Naj, Shipra Das et autres

us (code pays fourni par la source)

Increased alemtuzumab exposure correlates with improved responses in heavily pretreated R/R ALL patients: Analysis of the balli-01 trial

Nitin Jain, Nicolas Boissel, Daniel J. DeAngelo, Aravind Ramakrishnan et autres

us, fr (code pays fourni par la source)

Trial in progress: Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) nathali-01

Jeremy S. Abramson, Aravind Ramakrishnan, Emmanuel Bachy, Laurent Poirot et autres

us, fr (code pays fourni par la source)

Principles of benefit-risk

Phil Ambery, Adrian Kilcoyne, Daniel O’Connor

Medicines for patients with hepatic impairment

Phil Ambery, Adrian Kilcoyne, Daniel O’Connor

ICH E9 and estimands

Phil Ambery, Adrian Kilcoyne, Daniel O’Connor

Medicines for older people

Phil Ambery, Adrian Kilcoyne, Daniel O’Connor

Intellectual property

Phil Ambery, Adrian Kilcoyne, Daniel O’Connor

Data protection

Phil Ambery, Adrian Kilcoyne, Daniel O’Connor

Medicines for patients with renal impairment

Phil Ambery, Adrian Kilcoyne, Daniel O’Connor